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ABSTRACT:
This article describes the combination of whole-body autoradi-
ography with liquid extraction surface analysis (LESA) and mass
spectrometry (MS) to study the distribution of the tachykinin neu-
rokinin-1 antagonist figopitant and its metabolites in tissue sec-
tions of rats after intravenous administration of 5.0 mg/kg figopi-
tant. An overview of autoradiography results is presented together
with mass spectrometry identification and semiquantification of
parent drug and its metabolites based on LESA-MS. The quality
and accuracy of data generated by LESA-MS were assessed in
comparison with classic tissue extraction, sample cleanup, and
high-performance liquid chromatography analysis. The parent
drug and the N-dealkylated metabolite M474(1) (BIIF 1148) in vary-
ing ratios were the predominant compounds in all tissues investi-
gated. In addition, several metabolites formed by oxygenation,
dealkylation, and a combination of oxygenation and dealkylation
were identified. In summary, the LESA-MS technique was shown to
be a powerful tool for identification and semiquantification of figo-
pitant and its metabolites in different tissues and was complemen-
tary to quantitative whole-body autoradiography for studying the
distribution.
Introduction
Quantitative whole-body autoradiography (QWBA) is the imaging
method of choice to investigate the distribution of drug-related radio-
activity in all organs and tissues of an intact organism, such as an
animal carcass. With this technique, information on the concentration
of the entire drug-related radioactivity is gained. However, the actual
molecular entity—parent compound or metabolites—and their respec-
tive proportions of the radioactivity remains unknown. The conven-
tional approach to identify and quantify parent drug and metabolites in
tissues is the preparation of organ homogenates and sample analysis
by liquid chromatography combined with radiodetection and tandem
mass spectrometry (MS/MS). However, this approach is labor-inten-
sive, and some tissues (e.g., salivary glands) and tissue substructures
(e.g., renal inner and outer medulla) can be difficult or even impos-
sible to sample and extract. Surface sampling methods such as de-
sorption electrospray ionization, laser desorption ionization, direct
analyses in real time, or matrix-assisted laser desorption ionization
can speed up analysis time and cut overall costs compared with classic
tissue extraction and enable spatial resolution of different anatomical
substructures within a given organ (Reyzer et al., 2003).
Recently, a fully automated liquid extraction-based surface sam-
pling method for mass spectrometry (MS) analyses of drugs and
metabolites in thin tissue sections has been described (Van Berkel and
Kertesz, 2009; Kertesz and Van Berkel, 2010). This liquid extraction
surface analysis (LESA) method uses a liquid microjunction probe to
extract the analytes directly from the surface followed by automated
nano-electrospray analysis. Direct surface sampling methods deal
with high sample complexity, because no chromatographic separation
is involved. To maintain the high dynamic range and mass accuracy
across the whole mass range, an optimized strategy can be used by
collecting multiple adjacent single ion monitoring (SIM) windows
(Southam et al., 2007), if a continuous long and stable analyte signal
is obtained. For LESA-MS, the typical volume used for the microex-
traction of 1 to 2 l enables the long analyte signal (20 min) needed
for the SIM strategy, which cannot be accomplished by the other
surface sampling methods.
This article describes the investigation of tissue sections of rats
after intravenous administration of 5.0 mg/kg [14C]figopitant, a tachy-
kinin neurokinin-1 (NK1) antagonist (Ohmura et al., 2004). The
approach applied here involved no additional sample preparation step.
Tissue sections prepared for QWBA were used directly for LESA-MS
in a fast and robust method. An overview of autoradiography results
is presented together with the corresponding results of LESA-MS. The
quality and accuracy of data generated by LESA-MS are assessed in
comparison to classic tissue extraction, sample cleanup, and high-
performance liquid chromatography (HPLC) analysis. For a variety of
different tissues, this comparison was performed using two different
animals, whereas for liver, the same animal was used.
Materials and Methods
Materials. Figopitant hydrochloride [BIIF 1149 CL ((S,-N-[2-[3,5-
bis(trifluoromethyl)phenyl]ethyl]-4-(cyclopropylmethyl)-N-methyl--phenyl-1-
piperazineacetamide, monohydrochloride, monohydrate)] is an NK1 receptor an-
tagonist (Ohmura et al., 2004). Figopitant hydrochloride (batch no. RAL 105) and
Article, publication date, and citation information can be found at
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the synthetic reference compounds BIIF 1148 CL2 [(S,-N-[2-[3,5-bis(trifluoro-
methyl)phenyl]ethyl]-N-methyl--phenyl-1-piperazineacetamide, dihydrochlo-
ride)] and BIIF 1276 (mixture of diastereoisomers) were synthesized at Boehringer
Ingelheim GmbH and Co. KG (Biberach an der Riss, Germany). Radiolabeled
[14C]figopitant hydrochloride (batch no. Ks 447/23) was obtained from the isotope
chemistry laboratory of Boehringer Ingelheim and had a radiochemical purity (as
determined by HPLC) greater than 97.0%.
HPLC grade acetonitrile (ACN) and methanol were purchased from Merck
(Darmstadt, Germany). Formic acid (FA) (p.a.  98% purity) was purchased
from Sigma-Aldrich (Schnelldorf, Germany). Water was demineralized and
purified by distillation in house.
Study Conduct. Dose formulation. The formulation was prepared on the
day of dosing. The target dose was 5.0 mg/kg [14C]figopitant free base, which
corresponds to 5.52 mg/kg [14C]figopitant hydrochloride. The radiolabeled
substance (5.034 mg) was dissolved in 2.055 ml of phosphate buffer with a pH
of 6.0. The final concentration of intravenously administered test substance
solution was 2.21 mg/ml with a specific activity of 0.3877 MBq/mol.
Animal experiment. Male albino Wistar Hannover rats (in-house bred strain:
Chbb:THOM) with body weights ranging from 165 to 175 g were housed
individually in standard macrolon cages under standardized environmental
conditions (e.g., 12-h light/dark cycle). From 20 h before test substance
administration via oral gavage until sacrifice at 4 h after dosing, the animals
were fasted and tap water was available at any time. At 5 min, 4 h, 24 h, and
144 h after intravenous administration, one rat per time point was anesthetized
with halothane. For determination of radioactivity concentrations in whole
blood and plasma by liquid scintillation counting (LSC) as well as the packed
cell volume (hematocrit), blood samples were withdrawn from the retrobulbar
venous plexus immediately before sacrifice. While still under general anes-
thesia, the animals were sacrificed by inhalation of an overdose of chloroform.
After euthanasia, the rat carcasses were deep frozen in a saturated solution of
dry ice in ethanol. For verification purpose, two additional male albino Wistar
rats [strain: Crl:WI(Han)] were sacrificed at 4 h [Cmax] after intravenous
administration. One carcass was intended for QWBA, the other was dissected.
All tissues obtained by dissection were submitted to extraction (see Analysis of
Tissue Sections and Samples). The in vivo experiment was conducted entirely
in accordance with the German animal welfare law (Tierschutzgesetz, http://
www.gesetze-im-internet.de/tierschg/index.html).
Preparation of tissue sections. After removal of legs and tail, the frozen
carcass was set in a block of aqueous 3% (w/v) carboxymethyl cellulose and
mounted onto the stage of a CM 3600 cryomacrocut maintained at 24°C
(Leica Microsystems GmbH, Nussloch, Germany). For quantitation of radio-
activity in tissues, seven calibration standards of human whole blood spiked
with a 14C-labeled reference compound in concentrations ranging from 2 
103 to 2  106 dpm/ml were embedded in each block. Sagittal sections with a
target thickness of 30 m were obtained at up to 3 levels through the carcass:
(1) ocular bulb/kidney, (2) adrenal gland, and (3) pituitary gland/spinal cord
(median) at 22°C according to the method of Ullberg (1977). The sections,
mounted on transparent tape (4248 Tesafilm; Beiersdorf AG, Hamburg, Ger-
many) were freeze-dried for 24 h in the cryomacrocut. A thin layer of talcum
powder was applied to the dehydrated section-bearing tapes to avoid adhesion
and electrostatic charge effects.
Quantitative Whole-Body Autoradiography. The dehydrated and talcum-
ized sections were exposed on FUJI imaging plates (BAS-SR 2025; Fujifilm
Europe GmbH, Düsseldorf, Germany) for 7 days. After exposure, the imaging
plates were processed using the Bio-Imaging Analyzer FUJIX BAS 2000
(raytest GmbH, Straubenhardt, Germany). The tissues were anatomically iden-
tified by AIDA (raytest GmbH)-assisted superposition of electronic whole-
body autoradiogram and related scanned section. The concentrations of radio-
activity in the identified tissues were quantified using a calibration curve over
the (LSC controlled) range of radioactivity concentrations, which was created
based on the phosphor-stimulated luminescence measured in the image of the
FIG. 1. Autoradiogram of a male albino rat
at 4 h after intravenous administration of
5.0 mg/kg [14C]figopitant (sagittal section
at ocular bulb-kidney-level).
TABLE 1
Concentrations and half-lives of total drug-related radioactivity in tissues of
male albino rats after intravenous administration of 5.0 mg/kg [14C]figopitant
Organ System 5 min 4 h 24 h t1/2
Tissue ng-eqv/g ng-eqv/g ng-eqv/g h
Locomotor apparatus
Muscle cranial 8437 2972 671 N.D.
Muscle caudal 6936 2606 670 19.7
Digestive apparatus
Tongue 12,885 3786 891 N.D.
Salivary gland 10,729 8238 1877 20.3
Liver 5984 13,851 4793 31.2
Pancreas 17,869 12,820 4138 N.D.
Adipose tissue 467 537 113 27.1
Respiratory apparatus
Lung 24,769 10,036 1708 20.5
Urogenital apparatus
Renal cortex 19,088 8020 2627 N.D.
Testis 938 1510 633 95.6
Epididymis 1728 2290 1043 N.D.
Endocrine glands
Adrenal cortex 21,006 11,078 3447 N.D.
Pituitary 8110 7747 2350 N.D.
Cardiovascular system
Myocardium 13,504 4240 1207 N.D.
Spleen 7308 10,694 3306 N.D.
Thymus 3243 3372 1746 22.7
Bone marrow 4445 3910 1156 N.D.
Whole blood (LSC) 830 361 122 38.6
Plasma (LSC) 483 192 80 21.9
Central nervous system
Brain (total) 1912 122 50 32.7
Sense organ (eye)
Harderian gland 4132 13,941 6246 N.D.
Common integument
Skin (total) 1743 1997 606 N.D.
N.D., not determined.
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embedded [14C]-blood standards and their radioactivity concentrations in gen-
eral accord with the approach described by Schweitzer et al. (1987). The tissue
concentration data are expressed in terms of nanogram equivalent of [14C]figo-
pitant free base per gram of tissue (ng-eqv/g). The lower and upper limits of
quantification for the procedure were 32 to 33,625 ng-eqv/g. For the purpose
of quantification, it was assumed that all tissues analyzed had density and
quench characteristics similar to whole blood (as used for calibration stan-
dards). Depending on organ size, up to 4 subareas per tissue within a single
autoradiogram were defined for quantification and statistics [e.g., for the liver
16 subareas from 4 autoradiograms of one animal and time point with a
coefficient of variation (CV) of 10.2%].
Extraction of Tissues. The following tissues were homogenized and ex-
tracted 4 h after intravenous administration of 5 mg/kg [14C]figopitant to rat:
liver, kidney, lung, spleen, pancreas, myocardium, muscle, white fat, brown
fat, brain, salivary gland, thymus, stomach, testis, Harderian’s gland, epidid-
ymis, and pituitary. In addition, liver tissue obtained from the same rat that was
used for LESA-MS was homogenized and extracted for liquid chromatography
(LC)/radiometry/MS analysis. Liver was cut from the remainder of the frozen
carcass blocked in aqueous carboxymethyl cellulose after preparation of tissue
sections.
Typical sample preparation procedures are described as follows. Tissues
were homogenized in water (1 ml/g) using a Potter S homogenizer (B. Braun
Biotech International, Melsungen, Germany). Tissue homogenates were pro-
cessed by extensive extraction with 10 ml of 0.1% FA in 70% aqueous ACN,
0.1% FA in 80% aqueous ACN, and 0.1% FA in 100% ACN. Recoveries of
each extraction step were monitored by LSC measurement, and extractions
were continued until 95% of total radioactivity were extracted. The samples
were shaken for 3 min with a mechanical shaker and ultrasonicated exten-
sively, then centrifuged for 10 min at 4000 rpm. The extracts were combined
and concentrated by lyophilization. For solid-phase extraction, cartridges were
preconditioned with ACN and equilibrated with water containing 0.1% formic
acid. After applying the tissue extracts onto the column and rinsing with 0.1%
formic acid in water, the adsorbed material was eluted with 0.1% formic acid
in 80% aqueous ACN and 0.1% formic acid in 100% ACN. The combined
eluates were concentrated by lyophilization.
The samples were analyzed by LC nano-electrospray ionization MS (NSI-
MS) in the positive ion mode using a linear ion trap/Orbitrap hybrid mass
spectrometer (Thermo Scientific, Bremen, Germany) (Hu et al., 2005)
equipped with a TriVersa NanoMate nanospray ion source (Advion BioSci-
ences, Ithaca, NY) (Schultz et al., 2000; Ramanathan et al., 2007). The
instrument was coupled to a Berthold LB 509 (Berthold Technologies, Bad
Wildbad, Germany) radioactivity detection system.
LC separation of the metabolites was performed by an optimized method: a
YMC Triart column (YMC Europe GmbH, Dinslaken, Germany) (150 4.6 mm,
particle size 3m) with a YMC ODS-AQ guard column (10 4 mm, particle size
5 m) at a flow rate of 1000 l/min was used. The injection volume was set to 10
to 500l, and the column oven temperature was 40°C. The mobile phase consisted
of 10 mM ammonium formate solution acidified with 0.1% formic acid (mobile
phase A) and acetonitrile with 0.1% formic acid (mobile phase B). The following
gradient was applied: 0.0 to 3.0 min linear from 5 to 35% B; 3.0 to 35.0 min linear
from 35 to 50% B; 35.0 to 40.0 min linear from 50 to 95% B; 40.0 to 45.0 min
isocratic 95% B; and 45.1 to 50 min reequilibration at 5% B. For the LC-NSI-MS
FIG. 2. Metabolism pathways of figopitant (rectangle) in rats after intravenous infusion of 5.0 mg/kg [14C]figopitant to male albino rat. Structures of metabolites were
characterized by mass spectrometry.
421DISTRIBUTION OF FIGOPITANT AND ITS METABOLITES IN RAT TISSUE
 at A
SPET Journals on February 5, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
experiments, the LC flow (1.0 ml/min) was split postcolumn with approximately
170 l/min going to the TriVersa NanoMate and the remaining to the online
radioactivity detector. After an additional splitter within the TriVersa NanoMate,
approximately 600 nl/min went into the NSI source. The TriVersa NanoMate
software was operated in spray sensing mode to automatically change to the nozzle
for two consecutive times in case of clogging. The Orbitrap mass analyzer was
operated at a resolution of approximately 60,000 full width at half-maximum at
m/z 400 in the full-scan MS mode. High-resolution mass spectra were acquired in
the range of m/z 100 to 1200. Accurate mass measurement was performed after
external calibration using the manufacturer’s calibration mixture before LC-MS
investigations.
Sample Analysis by LESA-MS. Samples obtained from the freeze-dried,
30-m whole-body sections were analyzed using a linear ion trap LTQ/
Orbitrap hybrid mass spectrometer (Thermo Scientific) (Hu et al., 2005)
equipped with a TriVersa NanoMate nanospray ion source (Schultz et al.,
2000; Ramanathan et al., 2007). For sample extraction from the tissue sections,
1 to 2 l of solvent (ACN/water 50:50 with 0.1% FA) were used. Solvent was
dispensed on the tissue sample and aspirated again after 2 s. This step was
repeated 3 times. The spot that was extracted had a diameter of approximately
1 mm. The infusion rate was approximately 50 to 100 nl/min. Two separate
MS methods were designed for metabolite identification and metabolite quan-
tification. For metabolite identification, a method was designed using 400 scan
events alternating between MS and MS2 experiments in 5 Da steps with an
overlap of 2.5 Da in the range of m/z 250 to 750. For metabolite quantification,
a SIM scan method was applied using a mass window of the accurate mass of
the metabolites  2.5 Da. The relative abundance of metabolites was assessed
based on average MS peak intensity with a mass tolerance of 5 ppm. Concen-
trations of metabolites at the sample spots were calculated based on total
radioactivity within these spots, which were obtained from QWBA.
Data Analysis. The relative concentration of individual metabolites as
percentage of total drug-related material was calculated as follows:
c(Mi)
c(Mi): (percentage of total drug-related material)  A(Mi)/i A(Mi)  100
c(Mi): relative concentration of individual metabolite
A(Mi): peak area of individual metabolite
i A(Mi): sum of peak areas of all metabolites and parent detected within
the LESA run.
The absolute amounts of individual metabolites in nanogram per kilogram
were calculated based on the relative percentage of metabolites and the
absolute amount of radioactive compound as determined by autoradiography.
Results
Autoradiography Results. After intravenous administration of 5.0
mg/kg [14C]figopitant, the total drug-related radioactivity was quickly
(judged on the first time point at 5 min postdosing) and extensively
distributed into all tissues of the body, including significant levels in
the central nervous system. Four hours after intravenous administra-
tion, Cmax of total drug-related radioactivity were reached in liver,
spleen, thymus, testis, epididymis, Harderian gland, skin, and adipose
tissue (Fig. 1). Due to biliary excretion and presumably also gastro-
intestinal secretion, the highest amounts of radioactivity at 4 h post-
dosing were found in the gastrointestinal contents (chyme). Except for
the situation in testis with a very long half-life of approximately 4
days, total drug-related radioactivity was cleared from all other tissues
with half-lives of approximately 20 to 40 h (Table 1).
Extraction of Tissues. Tissue extractions were considered to be
essentially complete, because more than 96.9% of total sample radio-
activity was extracted for all tissues. Solid-phase extraction recoveries
were in the range of 90 to 110% of sample radioactivity. Metabolite
patterns were assessed using HPLC coupled to online radioactivity
detection, and metabolites were identified by LC-MS/MS measure-
ments. Chemical structures were elucidated by LC-MS/MS and by
comparison with synthetic reference compounds, if available. The
parent drug and the N-dealkylated metabolite M474(1) (BIIF 1148) in
varying ratios were the predominant compounds in all tissues. In
addition, several metabolites formed by oxygenation [M544(1),
M544(2) (BIIF 1276), and M544(3)], oxygenation and dehydrogena-
tion [M542(1)], dealkylation [M448(1)], and a combination of oxy-
genation, dehydrogenation, and dealkylation [M488(1), M490(1)]
were found.
A synopsis of figopitant metabolites in rat tissue is presented in
Fig. 2, and corresponding LC-MS data are depicted in Table 2. The
TABLE 2
LC-MS data of figopitant and metabolites (compounds are listed in order of nominal [M  H] masses)
Metabolite Code Synthetic Reference Compound Retention Time, min [M  H] Product Ions
m/z (	m, ppm) m/z (	m, ppm)
M448(1) 11.9 C21H24ON3F6 431.15526 (0.60), 360.11815 (3.95), 149.10732 (0.68)
448.18181 (0.31)
M474(1) BIIF 1148 14.5 C23H26ON3F6 360.11815 (0.73), 175.12298 (1.60)
474.19746 (0.99)
M488(1) 13.4 C23H24O2N3F6 175.12298 (0.46)
488.17672 (0.50)
M490(1) 12.7 C23H26O2N3F6 175.12298 (0.11)
490.19237 (0.10)
M542(1) 18.3 C27H30O2N3F6 229.16993 (1.78)
544.22367 (0.60)
M544(1) 16.1 C27H32O2N3F6 229.16993 (1.12)
544.23932 (0.34)
M544(2) BIIF 1276 24.2 C27H32O2N3F6 360.11815 (3.78), 229.16993 (0.85), 138.11515 (2.81)
544.23932 (0.79)
M544(3) 14.7 C27H32O2N3F6 229.16993 (7.9)
544.23932 (0.57)
M528(1) BIIF 1149 21.5 C27H32ON3F6 360.11815 (1.75), 229.16993 (1.05), 139.12298 (1.90)
528.24441 (1.44)
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TABLE 3
Comparison of radioactivity-based quantification and LESA quantification of figopitant and its metabolites in different tissues of two different animals
Tissue Metabolite
Relative Abundance
LESA CV LESA Accuracy LESA
Organ Extraction LESA1 LESA2 LESA3 LESA Mean
% % nmol/kg
Lung M474 42.2 57.9 51.6 40.5 50.0 18 118 13,242
M490 3.2 3.2 2.7 2.1 2.7 21 83 706
Figopitant 48.6 32.1 37.2 47.4 38.9 20 80 10,302
M542 1.0 BLQ 1.3 1.6 1.5 15 145 384
M544 5.0 6.8 7.2 8.4 7.5 11 149 1977
Spleen M474 42.8 54.7 58.4 60.5 57.9 5 135 22,196
M490 7.5 5.5 5.6 5.5 5.5 1 74 2122
Figopitant 45.2 33.7 31.1 27.8 30.9 10 68 11,840
M544 4.5 6.1 4.9 6.2 5.7 13 127 2199
Kidney (outer medulla) M474 59.2 69.9 71.5 69.2 70.2 2 119 18,250
M490 9.7 8.3 9.1 9.8 9.1 8 93 2357
Figopitant 31.1 21.9 19.4 21 20.8 6 67 5399
Salivary gland M474 24.1 50.7 47.7 45.2 47.9 6 199 12,949
M488 3.2 1.5 1.2 1.1 1.3 16 40 461
M490 3.2 4.2 3.6 3.2 3.7 14 115 1413
Figopitant 67.5 39.2 42.4 45.8 42.5 8 63 11,718
M544 2.0 4.4 5.1 4.8 4.8 7 238 2307
White fat M474 10.9 BLQ BLQ BLQ N.A. N.A. N.A. N.A.
Figopitant 89.1 100.0 100.0 100.0 100.0 N.A. 112 1257
Myocardium M474 66.0 77.0 76.7 78.5 77.4 1 117 9136
Figopitant 34.0 23.0 23.3 21.5 22.6 4 66 2668
Liver M448 8.6 3.6 3.4 2.9 3.3 11 38 1006
M474 53.6 62.1 61.4 63.2 62.2 1 116 18,978
M488 3.5 BLQ BLQ 0.9 0.9 N.A. 26 274
M490 19.5 12.4 11.7 15.6 13.2 16 68 4036
Figopitant 9.3 14.4 14.7 9.6 12.9 22 139 3934
M542 1.6 BLQ BLQ BLQ N.A. N.A. N.A. N.A.
M544 3.9 7.5 8.8 7.9 8.1 8 207 2460
Pancreas M448 2.4 BLQ BLQ 1.4 1.4 N.A. 58 437
M474 40.6 56.5 58.1 53.0 55.9 5 138 17,437
M488 4.9 BLQ 0.5 1.5 1.0 71 20 312
M490 9.1 7.6 9.3 6.7 7.9 17 86 2455
Figopitant 29.7 22.8 20.7 27.7 23.7 15 80 7407
M542 3.5 BLQ BLQ BLQ N.A. N.A. N.A. N.A.
M544 9.7 13.1 11.4 9.7 11.4 15 118 3561
Thymus M474 20.9 17.9 27.3 23.3 22.8 21 109 2785
Figopitant 72.2 69.7 63.1 68.7 67.2 5 93 8192
M542 4.4 1.8 0.9 0.9 1.2 43 27 146
M544 2.5 10.6 8.7 7.1 8.8 20 352 1073
Stomach M474 46.4 44.1 44.7 50.2 46.3 7 100 N.A.
M488 5.8 1.9 1.9 2 1.9 3 33 N.A.
M490 7.7 7.6 6.3 11.3 8.4 31 109 N.A.
Figopitant 32.6 39.6 35.6 28.7 34.6 16 106 N.A.
M542 4.7 0.6 4.5 BLQ 2.6 108 54 N.A.
M544 2.9 6.3 7 7.9 7.1 11 244 N.A.
Testis M474 7.7 4.4 8.1 7.2 6.6 29 85 131
Figopitant 72.8 78.9 78.5 81.1 79.5 2 109 1591
M544 19.6 16.7 13.4 11.7 13.9 18 71 279
Harder’s gland M474 12.7 16.0 19.8 24.5 20.1 21 158 6884
Figopitant 87.3 84.0 80.2 75.5 79.9 5 92 27,367
Epididymis M474 14.4 13.0 28.6 28.3 23.3 38 162 1162
Figopitant 74.1 70.2 62.5 53.5 62.1 13 84 3095
M544 11.5 16.7 8.8 18.2 14.6 35 127 726
Muscle M488 4.1 0.9 0.9 0.9 0.9 0 22 62
M474 38.9 56.9 50.7 59.1 55.6 8 143 3851
M490 3.7 2.6 0.9 4.1 2.5 63 68 176
Figopitant 53.7 35.4 44.0 30.2 36.5 19 68 2532
M542 1.5 BLQ BLQ BLQ N.A. N.A. N.A. N.A.
M544 2.1 4.2 3.5 5.6 4.4 24 211 307
Pituitary M448 0.8 0.2 0.2 0.3 0.2 25 29 95
M474 31.4 44.0 43.3 37.3 41.5 9 132 16,974
M488 2.7 1.1 0.8 0.6 0.8 30 31 341
M490 4.6 3.5 3.3 3.2 3.3 5 72 1362
Figopitant 48.8 46.1 46.5 50.8 47.8 5 98 19,535
M542 2.3 0.6 0.2 0.4 0.4 50 17 163
M544 9.4 4.5 6.0 7.4 6.0 24 63 2439
Brain (total) M474 27.7 11.4 34.3 27.6 24.4 48 88 97
Figopitant 72.3 88.6 65.7 72.4 75.6 16 105 301
Brown fat M474 60.0 53.7 50.8 54.2 52.9 3 88 7095
Figopitant 40.0 46.3 49.2 45.8 47.1 4 118 6318
BLQ, below limit of quantification; N.A., not applicable.
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relative abundance of metabolites (percentage of total radioactivity) in
different tissues is presented in Table 3.
Sample Analysis by LESA-MS. Thin tissue sections from a rat
administered figopitant intravenously were analyzed and compared
with extracted tissues of another rat. In addition, after obtaining tissue
sections, the remainder of the liver was cut from the critical micelle
concentration block for LC/radiometry/MS. Metabolite identification
in tissue sections was performed using MS optimized for maximal
sensitivity and MS/MS to facilitate the search for metabolites. For
semiquantification of metabolites, a SIM scan method (2.5 Da) for
the eight metabolites identified with the survey method (Table 2) was
applied. The signal levels of the SIM scans were consistent over the
analysis time of 5 min. The relative abundance of metabolites was
assessed based on extracted ion chromatograms with a mass tolerance
of 5 ppm (Table 3). For each tissue, three different spots were
analyzed by LESA-MS. The same spot could be analyzed at least 18
times, yielding the same metabolic pattern; however, the intensity of
the MS signal dropped. There was no major difference in metabolic
pattern of tissues when different solvent compositions (5% aqueous
ACN, 50% aqueous ACN) were used for extraction; however, the
signal intensity was higher with 50% ACN compared with 5% ACN.
LESA-MS of tissue sections showed that the drug substance and the
N-dealkylated metabolite M474(1) (BIIF 1148) were the predominant
compound in all tissues. There was no qualitative difference between
LESA analysis and HPLC analysis of extracted tissues, and all major
metabolites identified in tissue extracts were also found with LESA.
However, isobaric metabolites such as M544(1), M544(2), and
M544(3) cannot be distinguished by LESA-MS because there is no
chromatographic separation. The relative abundance of metabolites
(percentage of drug-related compounds) in different tissues quantified
using LESA is presented and compared with radioactive quantifica-
tion data in Table 3.
In addition, liver tissue obtained from the same rat that was used for
tissue sections was homogenized, extracted, and analyzed by LC/
radiometry/MS and compared with results obtained by LESA. The
relative abundance of metabolites (percentage of drug-related com-
pounds) and absolute metabolite concentrations are listed in Table 4.
Discussion
After intravenous administration of figopitant to rats, the parent
drug and the N-dealkylated metabolite M474(1) in varying ratios were
predominant in all tissues investigated. In addition, several metabo-
lites formed by oxygenation, dealkylation, and a combination of
oxygenation and dealkylation were identified. Extraction of tissues
followed by radiochromatographic analysis yielded the same qualita-
tive and comparable quantitative results as LESA-based analysis of
tissue sections. The experimental approach applied here involved no
sample preparation steps. Tissue sections prepared for autoradiogra-
phy were used directly for LESA-MS.
Analysis of the liver of the same animal by extraction and radio-
chromatography compared with LESA-based quantification are in
good agreement. The most prevalent compounds [M474(1), M490(1),
and figopitant] could be quantified by LESA-MS with accuracies
between 82 and 110%. For low abundant metabolites, integration of
chromatographic peaks is less accurate compared with higher abun-
dant metabolites. Therefore, LESA-MS-based and radiometric quan-
tification deviate more for lower abundant metabolites. Because there
is no chromatographic separation, the isobaric metabolites M544(1),
M544(2), and M544(3) cannot be distinguished by this methodology.
M544(1), M544(2), and M544(3) are low abundant metabolites, there-
fore the radiometric quantification becomes less accurate, especially if
one or two isomers are below the limit of radiometric quantification
(500 dpm on column).
For all other organ analysis, different animals were used for LESA-
MS-based and radiometric quantification, and therefore the interindi-
vidual variability has to be considered as well. The extent of the
interindividual variability can be seen when comparing the radiomet-
ric quantification of the liver extract of the two different animals
(Tables 3 and 4). For both animals, M474(1) was the major metabolite
(61.4 and 53.6% of total), followed by M490(1), accounting for 16.2
and 19.5%, respectively. The parent drug accounted for 11.7 and
9.3%. Metabolite M488(1) was apparently not present in significant
amounts in the animal used for LESA but was found in relevant
quantity in the animal used for tissue extraction and radiometric
quantification. In addition to the interindividual variability, there can
also be variability in respect to distribution of parent drug and me-
tabolites within certain organs and organ substructures, for example in
different regions of the brain. This has to be kept in mind when
homogenates that are an average over the whole tissue are compared
with the localized areas samples by LESA-MS. Furthermore, this
probably also contributes to higher CV values for LESA-MS of
metabolites in certain tissues.
In addition to these animal experimental limitations, MS-based
quantification without reference standards can only be considered to
be semiquantitative. MS response can vary significantly depending on
the analyte ionization efficiency, sample matrix, LC mobile phase,
etc. (Hop et al., 2005). Differences in ionization efficiency of com-
pounds with different physicochemical characteristics are in general
reduced by the application of chip-based NSI (Hop et al., 2005; Hop,
2006; Valaskovic et al., 2006; Wickremsinhe et al., 2006; Ramana-
than et al., 2007). Recently, the accuracy of nano-electrospray ion-
ization MS response of drug compounds and their respective metab-
olites from biological matrices compared with accurate radiometric
quantification was evaluated, and it has been demonstrated that nano-
electrospray mass spectrometry can be used for semiquantitation of
metabolites (Schadt et al., 2011). For LESA-MS, the accuracy of
semiquantification results was expected to be even higher, because no
chromatographic separation was used, and therefore different LC
mobile phase compositions and matrix effects could not contribute to
variations in MS response.
In conclusion, the LESA technique was found to be a powerful tool
for identification and semiquantitation of figopitant and its metabo-
lites in tissue sections. Figopitant and its N-dealkylated metabolite
M474(1) (BIIF 1148) in varying ratios were the predominant com-
pounds in all tissues. In this study, LESA-MS provided results that are
complementary to QWBA. With LESA-MS, major metabolites in a
variety of different tissues can be identified, and relative quantitation
of metabolites is achieved by MS. Furthermore, combination of LESA
TABLE 4
Comparison of radioactivity-based quantification and LESA quantification of
figopitant and its metabolites in liver of the same animal
Metabolite
Relative Abundance Absolute Quantification
AccuracyOrgan
Extraction
LESA
Mean
Organ
Extraction LESA
% nmol/kg %
M448 6.4 3.3 1952 1006 52
M474 61.4 62.2 18,724 18,978 101
M488 BLQ 0.9 BLQ 274 N.A.
M490 16.2 13.2 4940 4036 82
Figopitant 11.7 12.9 3568 3934 110
M542 BLQ BLQ BLQ BLQ N.A.
M544 4.3 8.1 1311 2460 188
BLQ, below limit of quantification; N.A., not applicable.
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with QWBA provides semiquantitation of absolute metabolite levels
in tissue.
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